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Identification of an isolated tumour cell with metastatic ability is important for predicting the recurrence and prognosis of gastric
cancer. A biological marker for evaluating the metastatic ability of gastric cancer cells has not yet been identified. We assessed vascular
endothelial growth factor receptor-1 mRNA expression by quantitative real-time reverse transcriptase-polymerase chain reaction.
Vascular endothelial growth factor receptor-1 mRNA in peripheral blood was more highly expressed in perioperative metastasis-positive
and postoperative recurrence cases than in normal control cases, early cancer cases and nonmetastatic advanced cancer cases. The
peripheral blood vascular endothelial growth factor receptor-1 mRNA-positive group was associated with advanced clinical stage, deep
invasion beyond the muscularis propria, lymphatic involvement, vascular involvement, lymph node metastasis, positive peritoneal
lavage cytology, preoperative metastasis and postoperative recurrence. Flow cytometry analysis disclosed that vascular endothelial
growth factor receptor-1 expressing cells in the peripheral blood were more abundant in cancer cases with metastases than in cases
without metastases. Our data suggest that the amount of positive cells may provide information on the clinical features of gastric
cancer, especially in regard to gastric cancer metastasis.
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Vascular endothelial growth factor (VEGF) plays an important role
in cancer progression. The receptors of VEGF consist of VEGFR1
(Flt-1), VEGFR2 (KDR/Flk-1) and VEGFR3 (Flt-4). VEGFR1 is a
receptor not only for VEGF, but also for placental growth factor
(PGF), and is associated with tumour progression and neovascu-
larization (Pajusola et al, 1992; Galland et al, 1993; Ferrara &
Davis-Smyth, 1997; Shibuya et al, 1999; Hiratsuka et al, 2001).
Furthermore, there are splicing variants from the original VEGFR1
protein. Kendall and Thomas (1993) reported that soluble VEGFR1
(sVEGFR1) is one of the splicing variants derived from the
membrane penetrating type VEGFR1 protein, and therefore there
is considerable difference between the soluble protein and the one
in this study. The sVEGFR1 competitively inhibits the binding
between VEGFR1 and its ligands, such as VEGF and PGF.
Moreover, Clark et al (1998) reported that sVEGFR1 exists
specifically in serum from pregnant women, and does not exist
in serum from men and nonpregnant women. For that reason we
did not assess sVEGFR1 protein in this study.
Recently, Kaplan et al (2005) reported that bone marrow
progenitor cells expressing VEGFR1 play an important role in the
development of malignant metastatic foci. Their finding suggests
that VEGFR1-expressing cells in the bone marrow or peripheral
blood may be related to cancer metastasis and recurrence. There
have been no reports studying the clinical and pathological
significance of VEGFR1 mRNA expression in the bone marrow and
peripheral blood of cancer patients up to the present time. We
have therefore studied its significance in gastric cancer patients,
and have demonstrated that patients with high VEGFR1 mRNA
expression in bone marrow or peripheral blood have significantly
higher metastasis and recurrence rates than those with low
VEGFR1 mRNA expression.
MATERIALS AND METHODS
Patients
Ninety gastric cancer patients who underwent surgical treatment in
the National Cancer Center Hospital, Japan, from 2001 to 2004
were enrolled in the study. Sixteen patients with no history of
cancer, who underwent abdominal operation in our hospital from
2001 to 2004, were recruited as noncancer controls. The mean
postoperative period was 9.8 months, ranging from 4 to 24 months.
The clinical stages and pathologic features of primary tumours
were defined according to the criteria of the Japanese classification
of gastric carcinoma (Japanese Research Society for Gastric
Received 4 December 2006; revised 5 April 2007; accepted 17 April
2007; published online 8 May 2007
*Correspondence: Dr M Mori; E-mail: mmori@beppu.kyushu-u.ac.jp
4These authors have equally contributed to this work.
British Journal of Cancer (2007) 96, 1723–1728
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sCancer, 1999). The ages of the 68 male and 38 female patients
ranged from 31 to 85 years. Written informed consent was
obtained from all patients. The total 106 patients were divided into
the following four groups: group 1 consisted of noncancer patients
(n¼16); group 2 consisted of early cancer patients, with tumours
that had invaded less than the entire submucosal layer (n¼30);
group 3 consisted of advanced cancer patients, where there was
evidence of deep invasion beyond the muscularis propria and no
preoperative distant metastasis (n¼30); and group 4 comprised
patients with metastasis and recurrence, where there were distant
metastases at the time of operation (i.e., liver and/or lung
metastasis, peritoneal dissemination) (n¼18), or, patients up to
April 2005, who developed postoperative recurrence (i.e., perito-
neal dissemination and distant metastasis) (n¼12). Additionally,
the 18 gastric cancer patients with metastases at the time of
operation had palliative therapies (gastrointestinal reconstruction
and control of bleeding), to improve patient quality of life.
Bone marrow and blood sampling
Aspiration of both peripheral blood and bone marrow was
conducted under general anaesthesia immediately before surgery.
The bone marrow aspirate was obtained from the sternum using a
bone marrow aspiration needle (MDTECH, Gainesville, FL, USA),
and peripheral blood was obtained through a venous catheter. The
first 1ml of both peripheral blood and bone marrow was discarded
to avoid contamination by epidermal cells. A 1ml sample of
peripheral blood and bone marrow was each immediately mixed
vigorously with 4ml of ISOGEN-LS (NIPPON GENE, Toyama,
Japan) and stored at  801C until RNA extraction.
Total RNA extraction and first-strand cDNA synthesis
Total RNA was extracted according to the ISOGEN-LS manufac-
turer’s protocols. All the clinical samples obtained from the
National Cancer Center Hospital were sent to our institute. The
reverse transcriptase reaction (RT) was performed as described
previously (Mori et al, 1995; Masuda et al, 2002). First-strand
cDNA was synthesized from 2.7mg of total RNA in a 30ml
reaction mixture containing 5ml5   RT reaction buffer (BRL,
Gaithersburg, MD, USA), 200mM dNTP, 100mM solution random
hexadeoxynucleotide primer mixture, 50U of RNasin (Promega,
Madison, WI, USA), 2ml 0.1M dithiothreitol and 100U of Molony
murine leukaemia virus RT (BRL). The mixture was incubated at
371C for 60min, heated to 951C for 10min, and then chilled on ice.
Quantitative RT–PCR
The sequences of VEGFR1 mRNA were as follows: sense primer, 50-
TCATGAATGTTTCCCTGCAA-30; and antisense primer, 50-GGAG
GTATGGTGCTTCCTGA-30. Ribosomal protein S27a (RPS27A) was
used as an internal control. The sequences of RPS27A primers were
as follows: sense primer, 50-TCGTGGTGGTGCTAAGAAAA-30; and
antisense primer, 50-TCTCGACGAAGGCGACTAAT-30. Real-time
monitoring of PCR reactions was performed using the Light-
Cyclert system (Roche Applied Science, Indianapolis, IN, USA)
and SYBR green I dye (Roche Diagnostics). Monitoring was
performed according to the manufacturer’s instructions, as
described previously (Masuda et al, 2003; Ogawa et al, 2004). In
brief, a master mixture was prepared on ice, containing 500ng of
cDNA of each gene, 2ml of LC DNA Master SYBR green I mix,
50ng of primers and 2.4mlo f2 5m M MgCl2. The final volume was
then adjusted to 20ml with water. After the reaction mixture was
loaded into the glass capillary tube, PCR was carried out under
the following cycling conditions: initial denaturation at 951C
for 10min, followed by 40 cycles of denaturation at 951C for 8s,
annealing at 681C for 8s and extension at 721C for 2s. After
amplification, the products were subjected to a temperature
gradient from 72 to 951C at 0.11C/s, under continuous fluorescence
monitoring to produce a melting curve of the products.
Flow cytometry analysis
To determine VEGFR1 protein expression in peripheral blood, we
obtained preoperatively 10ml of heparanized peripheral blood
from gastric cancer patients with or without distant metastasis.
Blood mononuclear cells were obtained by Ficoll density
centrifugation at 1500g for 30min. Phycoerythrin-conjugated
monoclonal antibody against human VEGFR1 was purchased
from R&D Systems (Minneapolis, MN, USA). Mononuclear cells
(1 10
6) were stained with VEGFR1 antibody after Fc receptor
blocking, and analysed by the BD FACS Vantaget SE flow
cytometry system. The data were analysed using CellQuest soft
ware (BD Biosciences, San Jose, CA, USA).
Data analysis
The expression levels of VEGFR1 and RPS27A mRNA were
determined by comparison with the cDNA from Human Universal
Reference Total RNA (Clontech, Palo Alto, CA, USA). After
proportional baseline adjustment, the fit point method was
employed to determine the cycle in which the log-linear signal
was first distinguishable from the baseline, and then that cycle
number was used as a crossing-point value. The standard curve
was produced by measuring the crossing point of each standard
value and plotting it against the logarithmic value of the
concentrations. Concentrations were calculated by plotting their
crossing points against the standard curve, and were adjusted by
RPS27A content. Taking into consideration the clinical application
of the current study, the 95% confidence interval was used as the
upper limit of a normal case cutoff value (bone marrow, 0.12;
peripheral blood, 0.059). The 95% value of a normal case according
to the reference intervals of the Clinical and Laboratory Standards
Institute (Sasse, 2000) was established, and the reference limit was
regarded as the cutoff value. Levels higher or lower than the cutoff
value were considered ‘positive’ and ‘negative’, respectively. The
sensitivity and specificity of the data were determined to evaluate
the legitimacy of the cutoff value.
Statistics
For continuous variables, the data were expressed as the
mean7s.d. The relationships between VEGFR1 mRNA expression
and the clinicopathological factors were analysed using the w
2-test
and Kruskal–Wallis test. All tests were analysed using JMP
software (SAS Institute Inc., Cary, NC, USA). Statistical signifi-
cance was determined from two-sided tests as Po0.05.
RESULTS
Expression of VEGFR1 mRNA in peripheral blood and
bone marrow of surgical gastric cancer patients
Figure 1 shows peripheral blood VEGFR1 mRNA levels of the four
groups. In peripheral blood, the mean expression level of VEGFR1
mRNA in group 4 (0.09970.055) was significantly higher than
all other groups (Po0.0001; group 1 (0.03370.05), group 2
(0.04470.039) and group 3 (0.04570.039)). It is of note that there
was no significant difference in VEGFR1 expression levels in the 18
cases with metastasis at the time of operation compared with the
12 cases with postoperative recurrence; however, 30 cases with
recurrence/metastasis expressed a significantly higher level
of VEGFR1 than the 60 gastric cancer cases without metastasis/
recurrence (Figure 2). In bone marrow samples, there was no clear
relationship between the expression level of VEGFR1 mRNA and
the progression of gastric cancer cases.
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gastric cancer patients with surgery
The correlations between the results for the VEGFR1 mRNA levels
and clinicopathological variables are summarized in Table 1. By
the predetermined cutoff values for bone marrow, 0.12, and
peripheral blood, 0.059, of the 90 patients there were 23 (25.6%)
and 34 (37.8%) estimated to be positive for VEGFR1 mRNA in
bone marrow and peripheral blood, respectively. Sensitivities with
these cutoff values were 66.7% in peripheral blood and 46.7% in
bone marrow, and specificities were 76.7% in peripheral blood and
85.0% in bone marrow. In the peripheral blood, a significantly
higher number of VEGFR1 mRNA positive cases belonged to the
following clinical subgroups: those in stages 3 and 4 (Po0.001),
invasion deeper than the muscularis propria (Po0.01), lymphatic
involvement (Po0.001), vascular involvement (Po0.0001), lymph
node metastases (Po0.0001), positive peritoneal lavage cytology
(Po0.001), perioperative overt metastases (e.g., liver or lung
Po0.05) and postoperative recurrence (Po0.01). In contrast, in
bone marrow, there was a significant difference observed that
correlated with the pathological stage (Po0.05), the incidence of
lymphatic involvement (Po0.05), lymph node metastases
(Po0.01), positive peritoneal lavage cytology (Po0.05) and the
presence of postoperative recurrence (Po0.01).
VEGFR1 expression in blood by flow cytometry
According to flow cytometry analysis, VEGFR1-positive cells in the
lymphocytes and monocytes of mononuclear cells isolated from
the peripheral blood of gastric cancer patients with metastasis
were increased over patients without metastasis (9.8. vs 2.5% in
representative study case) (Figure 3). In particular, VEGFR1-
positive cells in the fraction of monocytes in FS/SS plots were more
abundant in the metastatic patient (9.7%) than in the nonmeta-
static patient (2.4%).
DISCUSSION
In this study, we studied VEGFR1 mRNA expression in the bone
marrow and peripheral blood of patients with gastric cancer.
Patients with metastases and/or recurrence expressed higher levels
of VEGFR1 mRNA in the peripheral blood than nonmetastatic and
nonrecurring patients. Patients with a high level of VEGFR1 mRNA
expression in peripheral blood showed deeper tumour invasion in
the primary organ, positive vascular vessel or lymphatic vessel
invasion, positive lymph node metastasis and positive peritoneal
lavage cytology. Thus, the expression of VEGFR1 mRNA in the
peripheral blood may be associated with metastasis and recurrence
of gastric cancer.
The source of VEGFR1 mRNA in peripheral blood or bone
marrow in gastric cancer patients has not yet been elucidated.
We initially speculated that the original cells expressing VEGFR1
in gastric cancer patients are the haematopoietic progenitor cells
(HPCs). Lyden et al (2001) reported that the progression of
tumour vessels needs the cooperation of VEGFR1-positive HPCs
and VEGFR2-positive endothelial progenitor cells. In addition,
Kaplan et al (2005) reported that bone marrow-derived HPCs
express VEGFR1 home to tumour-specific premetastatic sites, and
form cellular clusters that provide a permissive niche for incoming
tumour cells before the arrival of tumour cells. Another possible
source may be mature vessel-derived endothelial cells, which
might be the largest source of VEGFR1-expressing circulating
endothelial cells (CECs) (Mancuso et al, 2001; Beerepoot et al,
2004). Contrary to our expectation, there was no significant difference
in the number of VEGFR1-expressing cells of CD133
þ/  CD31
þ
0.1
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VEGFR1 expression in peripheral blood
P<0.0001
Group 1
(n=16)
Group 4
(n=30)
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* *
* *
* *
* *
Figure 1 VEGFR1 mRNA expression in peripheral blood from gastric
cancer cases. Group 1 consisted of noncancer patients (n¼16). Group 2
consisted of early cancer patients, with tumours that invaded less than the
sub-mucosal layer (n¼30). Group 3 consisted of advanced cancer patients,
where there was evidence of deep invasion beyond the muscularis propria
and no preoperative distant metastasis (n¼30). Group 4 was the
metastasis and recurrence patient group, where there were distant
metastases at the time of operation (i.e., liver and/or lung metastasis,
peritoneal dissemination) and who developed postoperative recurrence
(e.g., peritoneal dissemination and distant metastasis) (n¼30). The mean
expression level of VEGFR1 mRNA in group 4 was significantly higher than
all other groups (Po0.0001, respectively).
0.1
0.2
0.3
Not significant
VEGFR1 expression in peripheral blood
Metastasis−
recurrence−
(n=60)
Metastasis+
(n=18)
Recurrence+
(n=12)
P<0.0001
* *
* *
* *
Figure 2 VEGFR1 expression with or without metastasis and recurrence.
There is no significant difference between patients with metastasis at the
time of operation and patients with postoperative recurrence. The higher
VEGFR1 expression was observed in patients with metastasis pre- and
postoperatively in comparison with gastric cancer patients without
metastasis (Po0.0001, respectively).
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metastasis and a patient without metastasis (data not shown). Our
present study revealed that the original cells producing VEGFR1
may be monocytes. Bone marrow and peripheral blood samples
contain many white blood cells, including monocytes, in addition to
a few circulating CECs or HPCs. In patients with advanced cancer,
IL-10 or IL-12 are expressed more frequently than in patients with
early cancer or normal volunteers (Sugai et al, 2004). These findings
indicate that the monocyte–macrophage lineage is activated in
patients with advanced cancer, and VEGFR1 may be expressed by
this lineage (Sawano et al,2 0 0 1 ) .I ng e n e r a l ,t h em e t a s t a t i cp a t h w a y
in gastric cancer is not haematogenous, and therefore, the
responsible cells expressing VEGFR1 may be monocytes and not
HPCs and CECs. A last possibility is that VEGFR1 originates from
circulating cancer cells in the bone marrow or peripheral blood (Fan
et al, 2005; Yang et al, 2006). However, the number of circulating
cancer cells is very low, which allow us to ignore the possibility that
cancer cell are the origin of VEGFR1 expression.
To our knowledge, this study is the first to describe the
detection of VEGFR1 mRNA in the circulating blood of cancer
patients. It will be very important to determine in advanced cases
which cells produce VEGFR1 mRNA in the peripheral blood. In
brief, using flow cytometry analysis to detect VEGFR1-expressing
cells in blood, we found that the number of VEGFR1-positive cells
in peripheral blood was distinctly larger in a gastric cancer case
with metastasis than in a case without metastasis. In gastric cancer
cases with metastases, VEGFR1-positive monocytes were more
abundant than the other cells, including CECs and HPCs. Because
there are much fewer CECs and HPCs than monocytes, the
VEGFR1 mRNA which we detected in this study may be of
monocyte origin. That VEGFR1-positive HPCs and CECs may also
contribute to gastric cancer progression has been supported by
several reports. Additional study is needed to verify the function of
individual VEGFR1-expressing cells.
In conclusion, the evaluation of VEGFR1 mRNA in the
peripheral blood samples of gastric cancer patients could be very
important, because it may be a valuable marker for cancer
metastasis or recurrence. When considering the clinical
application of this marker, it is a fortuitous finding, because
from a practical standpoint, it is easier to obtain peripheral
Table 1 Relationship between clinicopathological variables and the VEGFRI mRNA expression in peripheral blood bone and marrow from gastric cancer
cases
VEGFR1 -bone marrow VEGFR1 -peripheral blood
Positive Negative Positive Negative
Features n (n¼23) (n¼67) P value n (n¼34) (n¼56) P-value
Sex
Male 61 16 45 0.83 61 26 35 0.17
Female 29 7 22 29 8 21
Age (mean7s.d.) 62.7713.4 59.6711.1 0.14 62.5711.2 59.2712 0.1
Stage
1 and 2 55 9 46 o0.05 55 13 42 o0.001
3 a n d 4 3 51 4 2 1 3 52 1 1 4
Invasion depth
Slighter than submucus 28 4 24 0.09 28 5 23 o0.01
Deeper than muscularis propria 60 19 43 62 29 33
Lymphatic involvement
Negative 58 10 48 o0.05 58 14 44 o0.001
Positive 32 13 19 32 20 12
Vascular involvement
Negative 65 14 51 0.16 65 16 49 o0.0001
Positive 25 9 16 25 18 7
Lymph node metastasis
Negative 62 10 52 o0.01 62 15 47 o0.0001
Positive 28 13 15 28 19 9
Peritoneal lavage cytology
Negative 71 14 57 o0.05 71 20 51 o0.001
Positive 19 9 10 19 14 5
Peritoneal dissemination
Negative 82 20 62 0.42 82 30 52 0.46
Positive 8 3 5 8 4 4
Perioperative overt metastasis
Negative 72 16 56 0.15 72 23 49 o0.05
Positive 18 7 11 18 11 7
Postoperative recurrence
Negative 78 16 62 o0.01 78 25 53 o0.01
Positive 12 7 5 12 9 3
s.d.¼standard deviation.
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goal will be to evaluate the protein level of VEGFR1 in blood
samples of cancer patients, to determine its practical use as a
tumour marker.
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